Biosimilar Insulin: Why Novo Knows No Fear
Executive Summary
Even after the largest pharmaceutical company in the sector, Pfizer Inc., announced it was laying a stake in the biosimilar insulin market, Danish diabetes leader Novo Nordisk A/S – about one-fifth the size of Pfizer in sales terms, although its market cap is just under half of Pfizer's – didn't flinch.
You may also be interested in...
Price Isn't Enough: Sandoz Hones Biosimilars Strategy With Lessons From Omnitrope
As FDA fleshes out the beginnings of a biosimilar regulatory pathway in the U.S., Novartis AG's generics business Sandoz is starting to draw important lessons in how to effectively commercialize copy-cat biologics.
Pfizer Teams Up With Biocon In Bid to Dominate Global Biosimilar Insulin Market
Pfizer tells analysts the deal will have an incremental not "instrumental" impact on its established products and emerging markets strategy.
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”